CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).

被引：30

作者：

Abramson, Jeremy S.

Palomba, Maria Lia

Gordon, Leo I.

Lunning, Matthew Alexander

Arnason, Jon E.

Forero-Torres, Andres

Wang, Michael

Albertson, Tina M.

Allen, Tara

Sutherland, Claire

Xie, Benhuai

Garcia, Jacob

Siddiqi, Tanya

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[4] Univ Nebraska Med Ctr, Omaha, NE USA

[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Juno Therapeut Inc, Seattle, WA USA

[9] City Hope Comprehens Canc Ctr, Duarte, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.7513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7513

引用

页数：5